Basic | |
---|---|
Market Cap | $1.94B |
Price | $8.91 |
52 Week Range | 3.53-23.86 |
Beta | 2.04 |
Margins | |
Gross Profit Margin | 59.57% |
Operating Profit Margin | -34.74% |
Net Profit Margin | -35.77% |
Valuation (TTM) | |
P/E Ratio | -4.49 |
Price to Sales Ratio | 1.73 |
Price to Book Ratio | -3.06 |
PEG Ratio | -0.32 |
Biotechnology
Healthcare
1,543
1995-12-05T00:00:00.000Z
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
240 268 2000
21 Firstfield Road, Gaithersburg, MD, 20878, US
0001000694